Our Approach:
Identify diseases with mTOR pathway genomic alterations and strong evidence of mTOR involvement in pathology of disease
Target genomically defined subgroups across cancer types with mTOR pathway alterations (e.g., TSC1, TSC2) who are most likely to respond to mTOR treatment
Investigate and develop albumin-bound nanoparticle therapies for appropriate patient populations